Probiotic Strains and Selection

Walking into a health-food store probiotic aisle is one of the more confusing experiences in modern supplement shopping. Dozens of brands, billions of CFU advertised, claims ranging from "immune support" to "complete digestive wellness" — and almost no information on what specific strain at what dose was tested for which condition. The actual science is much more precise than the marketing implies. The 2014 ISAPP consensus statement (Hill et al.) established that a probiotic is "live microorganisms that, when administered in adequate amounts, confer a health benefit on the host," and that the relevant biology is strain-specific: Lactobacillus rhamnosus GG is not interchangeable with Lactobacillus rhamnosus HN001 just because they share a species name. This deep-dive walks through the genus-species-strain naming convention, the strain-by-condition evidence map, CFU dose thresholds, refrigerated vs shelf-stable formulations, the rise of spore-based probiotics, why Saccharomyces boulardii is uniquely useful, and the practical buying guide that maps a clinical goal to a specific product.

Table of Contents

  1. Why Strain Specificity Matters
  2. The Genus-Species-Strain Naming Convention
  3. The Strain-by-Condition Evidence Map
  4. CFU Counts and Dose Thresholds
  5. Refrigerated vs Shelf-Stable Formulations
  6. Enteric Coating and Gastric Survival
  7. Single-Strain vs Multi-Strain Formulas
  8. Spore-Based Probiotics (Bacillus coagulans, B. subtilis)
  9. Saccharomyces boulardii — The Only Yeast Probiotic
  10. The Zmora Personalized Response Finding
  11. Regulatory Wild-West and Quality Control
  12. Practical Buying Guide by Clinical Goal
  13. Key Research Papers
  14. Connections

Why Strain Specificity Matters

The single most important concept for probiotic supplementation is that strains matter, not just species or genera. Lactobacillus rhamnosus GG (also called LGG) and Lactobacillus rhamnosus HN001 belong to the same species but are different organisms with different genome content, different surface molecules, different metabolic profiles, and different clinical effects.

The mechanism for strain-level differences includes:

The clinical consequence is that Lactobacillus rhamnosus GG has solid evidence for antibiotic-associated diarrhea prevention and atopic eczema prevention in high-risk infants, while Lactobacillus rhamnosus HN001 has solid evidence for postpartum depression reduction and infant atopic prevention. The two are not interchangeable; picking the wrong one for the wrong indication is likely to produce no effect at all.

This is the inverse of how most consumers think about probiotics. The marketing language and the supplement aisle layout encourage you to think of "probiotics" as a category — like "vitamins" — where the specific product doesn't matter much. The science says the opposite: probiotic effects are strain-specific in the way that drug effects are molecule-specific.

Back to Table of Contents

The Genus-Species-Strain Naming Convention

The proper naming of a probiotic strain has three components, in order:

  1. Genus — the broader taxonomic group, capitalized and italicized. Examples: Lactobacillus, Bifidobacterium, Saccharomyces, Bacillus, Streptococcus, Lactococcus, Escherichia
  2. Species — the narrower group within the genus, lowercase and italicized. Examples: rhamnosus, plantarum, infantis, boulardii, coagulans, thermophilus
  3. Strain — the specific isolate, usually an alphanumeric identifier in roman type. Examples: GG, HN001, 35624, CNCM I-745, DSM 17938, NCC3001, BB-12, La-5

A complete proper name therefore looks like: Lactobacillus rhamnosus GG, or Bifidobacterium animalis subsp. lactis BB-12, or Saccharomyces boulardii CNCM I-745. A product label that says only "Lactobacillus acidophilus" without a strain identifier is providing roughly the same level of information as a drug label that says "antibiotic" without specifying which one.

One complication is that taxonomic revisions in 2020 split the historical Lactobacillus genus into 25 new genera. The probiotic strains formerly called Lactobacillus casei, L. paracasei, L. rhamnosus, L. plantarum, and L. reuteri are now technically Lacticaseibacillus casei, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, Lactiplantibacillus plantarum, and Limosilactobacillus reuteri. The literature and the supplement industry have lagged the renaming — most product labels still use the historical Lactobacillus names. This deep-dive uses the traditional names because they are what consumers will see on labels, but be aware that scientific literature increasingly uses the new genus names.

Back to Table of Contents

The Strain-by-Condition Evidence Map

The following table summarizes the strain-by-condition evidence in clinical use. For each indication, the strains with the strongest randomized-trial evidence are listed, along with the typical commercial product names.

For each entry, the strain (not just the species) is what matters. L. rhamnosus GG is not L. rhamnosus HN001. The Align product is specifically B. infantis 35624 and is not interchangeable with other "B. infantis" preparations. The BioGaia product is specifically L. reuteri DSM 17938 and is the strain that has the colic and the H. pylori evidence; other L. reuteri strains may or may not produce the same effects.

Back to Table of Contents

CFU Counts and Dose Thresholds

Probiotic doses are expressed in colony-forming units (CFU), a measure of the number of viable organisms in the dose. Modern probiotic products typically range from 1 billion to 200 billion CFU per dose, with some megadose products advertising 1 trillion CFU. The dose-response relationship is real but nonlinear and condition-specific.

General principles from the clinical trial literature:

"More CFU is better" is not generally true. Higher doses do not produce proportionally larger effects in most indications, and very high doses may produce side effects (bloating, gas, transient diarrhea) without additional benefit. Match the dose to the trial-validated dose for the specific indication being targeted.

A critical caveat: the CFU count on the label is typically the count at the time of manufacture, not at the time of consumption. Live organism count drops over time due to ambient temperature exposure, especially if the product is not refrigerated. A bottle labeled "10 billion CFU" may contain 1-3 billion CFU by the time the consumer takes the last capsule near the end of the bottle's shelf life. Choose products that guarantee CFU count "through expiration" (the AGA recommends this language) rather than just at manufacture.

Back to Table of Contents

Refrigerated vs Shelf-Stable Formulations

Refrigerated probiotic products were historically considered superior because cold storage extends the viability of most Lactobacillus and Bifidobacterium strains. The major refrigerated brands — Jarrow, Renew Life, Garden of Life refrigerated lines — promote refrigeration as a quality differentiator.

The newer shelf-stable formulations use one or more of the following strategies to maintain viability without refrigeration:

Practical guidance: refrigerated products are still typically the safest choice for traditional Lactobacillus and Bifidobacterium formulations, especially for products from smaller brands without extensive stability testing. Shelf-stable products from major brands with documented stability testing through expiration (Culturelle, Florastor, BioGaia, Align, Jarrow's spore-based lines) are reasonable choices, particularly for travel. Avoid shelf-stable generic store-brand products without strain-level disclosure and documented stability testing.

Back to Table of Contents

Enteric Coating and Gastric Survival

Gastric acid is the first major challenge facing an ingested probiotic. Gastric pH in the fasting state is around 1.5-2; in the postprandial state it rises to around 4-5. Most Lactobacillus and Bifidobacterium strains have limited acid tolerance — survival through the stomach is typically estimated at 1-10%, with substantial strain variation. Bile acid exposure in the duodenum kills additional organisms.

Strategies that improve gastric survival include:

The transient-passage paradigm developed by Sonnenburg, Knight, Zmora, and others reframes the survival question. Most probiotic strains do not permanently colonize the gut even when delivered in high numbers. They pass through over a few days, exerting effects during transit, and then leave. Whether 1% or 10% of dosed organisms survive the stomach matters less than whether the surviving fraction is high enough (and stays present for long enough) to deliver the intended signaling effect. For most indications, the trial-validated dose has been picked to deliver adequate live organisms past the stomach in the typical patient; you do not need to over-engineer the delivery further.

Back to Table of Contents

Single-Strain vs Multi-Strain Formulas

The supplement industry has moved heavily toward multi-strain formulations, often listing 10-20 different strains in a single product with marketing language about "broad-spectrum support" or "comprehensive microbiome diversity." The clinical evidence is more nuanced.

Arguments for multi-strain formulas:

Arguments for single-strain formulas:

Practical recommendation: for a specific clinical indication, use a single-strain or trial-validated multi-strain product with documented evidence for that indication. For general "gut support" or "microbiome diversity" maintenance in healthy adults, a multi-strain formula is reasonable but the evidence base is weaker than for targeted use.

Back to Table of Contents

Spore-Based Probiotics (Bacillus coagulans, B. subtilis)

Spore-forming probiotics — Bacillus coagulans GBI-30 6086 (Ganeden BC30), Bacillus subtilis DE111, Bacillus clausii — have grown rapidly in market share over the past decade. The spore form is a dormant, environmentally resistant cell that survives heat, humidity, and gastric acid much better than vegetative Lactobacillus cells. Spores germinate in the small intestine, becoming metabolically active vegetative cells that exert probiotic effects for the duration of transit, then sporulate again or die in the colon.

Advantages of spore-based probiotics:

The clinical evidence is growing but generally smaller than for traditional Lactobacillus/Bifidobacterium strains. Bacillus coagulans GBI-30 has trial evidence in IBS, post-exercise recovery, and immune support; B. subtilis DE111 in functional bowel symptoms and athletic performance; B. clausii as a long-standing pediatric diarrhea treatment in Europe. For most validated indications (AAD prevention, CDI prevention, IBS first-line probiotic, atopic eczema), the traditional Lactobacillus/Bifidobacterium/S. boulardii strains still have the strongest evidence base.

A caution: not all Bacillus species are safe as probiotics. Bacillus cereus in particular is a known foodborne pathogen producing emetic and diarrheal toxins, and contamination of probiotic products with B. cereus has been documented. Choose spore-based probiotic products from major brands with documented species identification testing.

Back to Table of Contents

Saccharomyces boulardii — The Only Yeast Probiotic

Saccharomyces boulardii CNCM I-745 (marketed as Florastor in the United States, Codex in some other countries) is uniquely useful in the probiotic toolkit because it is a yeast, not a bacterium. This single biological fact produces several practical consequences that distinguish it from all other probiotics.

The key consequences:

The standard dose is 250 mg twice daily (each 250 mg capsule contains approximately 5 billion CFU), for the duration of antibiotic exposure plus 1-2 weeks afterward in AAD/CDI prevention, or for 4 weeks in IBS, or for the duration of travel plus 1-2 days in traveler's diarrhea prevention.

The contraindications are specific: severely immunocompromised patients and patients with central venous catheters in place have a small risk of S. boulardii fungemia, which has been documented in case reports. The Yelin 2019 study found probiotic-derived bloodstream infections in ICU patients, including S. boulardii cases. The risk is low but not zero, and the strain should be avoided in these populations.

Back to Table of Contents

The Zmora Personalized Response Finding

The 2018 Zmora N et al. Cell paper from the Elinav lab in Israel reframed how researchers think about probiotic colonization. The investigators gave a standard 11-strain multi-strain probiotic to healthy volunteers and then directly sampled the mucosal microbiome via colonoscopy and upper endoscopy — not stool, which is just the lumen contents.

The findings were striking. Volunteers fell into two clear groups:

The host features that predicted resistance vs permissiveness included baseline microbiome composition, baseline immune gene expression in the gut mucosa, and host genetic factors. Stool sampling completely missed the difference — probiotic strains showed up in stool from both groups, even though only one group had actual mucosal colonization.

The implication is that probiotic response is highly individual, and that "trying a strain for a few weeks and seeing if it helps" is the rational empirical approach for many indications. A strain with good population-level trial evidence may not work for any individual patient if they happen to be in the resistant phenotype. Conversely, an individual patient may have a strong response to a strain that has only modest population-level evidence.

A second Zmora-lab finding from the same 2018 issue of Cell: in patients given a course of antibiotics followed by probiotic supplementation, the probiotic supplementation actually delayed the recovery of the native microbiome compared to no intervention or autologous fecal microbiota transplant. This is a counterintuitive result and is part of the reason for continued caution around routine probiotic use after antibiotic courses without a specific indication beyond AAD prevention.

Back to Table of Contents

Regulatory Wild-West and Quality Control

In the United States, probiotics are regulated as dietary supplements under the 1994 Dietary Supplement Health and Education Act (DSHEA), which means the FDA does not require pre-market approval of efficacy or safety for the specific product. Manufacturers are required to follow Good Manufacturing Practices (GMP), to make truthful and non-misleading label claims, and to ensure the product is safe — but the enforcement model is largely reactive (FDA acts on reports of harm) rather than proactive.

The consequence is real quality variability. Independent testing organizations (ConsumerLab, Labdoor, NSF International) have repeatedly documented probiotic products that:

Practical quality-control guidance for buying probiotics:

Back to Table of Contents

Practical Buying Guide by Clinical Goal

The following are evidence-based first-choice products for specific common clinical goals. Brand names are listed as examples of products that contain the trial-validated strain; equivalent products from other manufacturers that contain the same strain identifier are equally valid.

Back to Table of Contents

Key Research Papers

  1. Hill C et al. (2014). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology. — PubMed
  2. Sniffen JC et al. (2018). Choosing an appropriate probiotic product for your patient: an evidence-based practical guide. PLOS ONE. — PubMed
  3. Zmora N et al. (2018). Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell. — PubMed
  4. Suez J et al. (2018). Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell. — PubMed
  5. Sanders ME (2008). Probiotics: definition, sources, selection, and uses. Clinical Infectious Diseases. — PubMed
  6. Whorwell PJ et al. (2006). Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. American Journal of Gastroenterology. — PubMed
  7. Capurso L (2019). Thirty years of Lactobacillus rhamnosus GG: a review. Journal of Clinical Gastroenterology. — PubMed
  8. McFarland LV, Bernasconi P (1993). Saccharomyces boulardii: a review of an innovative biotherapeutic agent. Microbial Ecology in Health and Disease. — PubMed
  9. Konuray G, Erginkaya Z (2018). Potential use of Bacillus coagulans in the food industry. Foods. — PubMed
  10. Salminen S et al. (2021). The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nature Reviews Gastroenterology & Hepatology. — PubMed
  11. Zheng J et al. (2020). A taxonomic note on the genus Lactobacillus: description of 23 novel genera. International Journal of Systematic and Evolutionary Microbiology. — PubMed
  12. Yelin I et al. (2019). Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients. Nature Medicine. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents